-
ECONOMIC BURDEN AND COST EFFECTIVENESS OF ADVANCED GALLBLADDER CANCER TREATMENT IN NORTHEAST INDIA: A DUAL PHASE ASSESSMENT
Mar 18, 2026, 21:38 PM -
ASSOCIATION BETWEEN INTRA- AND POST-OPERATIVE SURGICAL COMPLICATIONS AND HEALTH ECONOMIC OUTCOMES IN PATIENTS UNDERGOING ROUX-EN-Y GASTRIC BYPASS: A RETROSPECTIVE DATABASE ANALYSIS
Mar 18, 2026, 21:38 PM -
REAL-WORLD TREATMENT PATTERNS AND HOSPITALIZATION FREQUENCY OF ASTHMA IN THE BRAZILIAN PUBLIC HEALTH SYSTEM
Mar 18, 2026, 21:38 PM -
DYNAMIC POPULATION MODELING FOR TOBACCO HARM REDUCTION - A TIME-SERIES APPROACH
Mar 18, 2026, 21:38 PM -
EXPLORING PREFERENCES FOR LYME DISEASE VACCINES IN THE UNITED STATES: A LATENT CLASS APPROACH
Mar 18, 2026, 21:38 PM -
ENHANCING TRANSFUSION MEDICINE EFFICIENCY THROUGH NAT SYSTEM TECHNOLOGY INNOVATION
Mar 18, 2026, 21:38 PM -
AI AGENT FOR AUTOMATED QUALITY CHECK OF MS EXCEL BASED COST-EFFECTIVENESS MODELS
Mar 18, 2026, 21:38 PM -
EMERGING PATTERNS OF GLP-1 MICRODOSING IN A LARGE REAL-WORLD POPULATION
Mar 18, 2026, 21:38 PM -
DECISION MODEL EVALUATING CLINICAL EVENT-RELATED COSTS OF PERSISTING WITH APIXABAN COMPARED WITH SWITCHING TO RIVAROXABAN AFTER A BLEEDING EVENT IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
COST OF 5-YEAR PROGRESSION FREE SURVIVAL ANALYSIS OF TRIPLE-CLASS EXPOSED PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA TREATED WITH CILTACABTAGENE AUTOLEUCEL IN THE BRAZILIAN PRIVATE HEALTH SYSTEM
Mar 18, 2026, 21:38 PM -
REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEW (REAL-SLR) CAPTURES A 2025 STANDARD-OF-CARE (SOC) SHIFT DRIVEN BY ANTIBODY-DRUG CONJUGATES (ADCS) IN UROTHELIAL CARCINOMA (UC): IMPLICATIONS FOR HEALTH TECHNOLOGY ASSESSMENTS (HTAS)
Mar 18, 2026, 21:38 PM -
COST-BENEFIT ANALYSIS OF TUMOR TREATING FIELDS PLUS RADIOSURGERY FOR BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER
Mar 18, 2026, 21:38 PM -
VALIDATION OF THE REAL-Q (REAL-WORLD EVALUATION ASSESSMENT LIST FOR QUALITY) TOOL
Mar 18, 2026, 21:38 PM -
THE ASSOCIATION BETWEEN PNEUMOCOCCAL VACCINATION HISTORY AND THE INCIDENCE OF PNEUMONIA AND HEALTHCARE RESOURSE USE IN RURAL RESIDENTS IN JAPAN
Mar 18, 2026, 21:38 PM -
ECONOMIC IMPACT OF TARDIVE DYSKINESIA AMONG HOSPITALIZED SCHIZOPHRENIA PATIENTS: EVIDENCE FROM US ADMINISTRATIVE DATA
Mar 18, 2026, 21:38 PM -
A MULTI-AGENT GENAI SYSTEM FOR TRACEABLE, MULTI-COUNTRY LANDSCAPE ASSESSMENT IN MASH
Mar 18, 2026, 21:38 PM -
SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS AND TREATMENT EFFECT MODIFIERS IN NON-MUSCLE INVASIVE BLADDER CANCER
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF REMIBRUTINIB FOR MODERATE TO SEVERE CHRONIC SPONTANEOUS URTICARIA IN THE U.S.
Mar 18, 2026, 21:38 PM -
ADHERENCE AND PERSISTENCE IN US REAL-WORLD NEW PREP USERS: CABOTEGRAVIR VS EMTRICITABINE/TENOFOVIR ALAFENAMIDE
Mar 18, 2026, 21:38 PM -
THE IMPACT OF MEDICATION ADHERENCE ON REAL-WORLD CLINICAL AND ECONOMIC OUTCOMES: A SCOPING REVIEW OF REAL-WORLD EVIDENCE
Mar 18, 2026, 21:38 PM
